Results 151 to 160 of about 96,501 (333)
ASMA NO PÚBLICO PEDIÁTRICO: PREVENÇÃO DE CRISES E MANEJO CLÍNICO [PDF]
Mayara Hellen de Sousa Moreira +6 more
openalex +1 more source
Genetic Insights Into Allergic Contact Dermatitis: Reassessing the Role of LCE3C_LCE3B Deletion
Contact Dermatitis, EarlyView.This study found no significant association between the LCE3C_LCE3B deletion and allergic contact dermatitis or polysensitisation in Tunisian patients, suggesting that other genetic or environmental factors may contribute to disease susceptibility. ABSTRACT Background Allergic contact dermatitis (ACD) is a multifactorial inflammatory skin disorder ...
Zeineb Ben Lamine +10 more
wiley +1 more source
Headache: The Journal of Head and Face Pain, EarlyView.Abstract Background Despite optimized therapy, up to 30% of patients with trigeminal neuralgia (TN) experience treatment failure. To date, there is limited and low‐quality data available on rescue strategies for this subset of patients. This study describes clinical outcomes associated with intravenous (IV) magnesium sulfate and methocarbamol, with or ...
Bradley Ong +5 more
wiley +1 more source
Novas Perspectivas Acerca do Contexto Inflamatório Th2 Na Asma
, 2015 Marcos Paulo Amelda Souza +1 more
openalex +2 more sources
International Endodontic Journal, EarlyView.ABSTRACT Aim Artificial intelligence (AI) has the potential to aid clinicians in assessing case difficulty in endodontics. The objectives of this study were to develop and validate deep learning models for the detection of clinically negotiable MB2 canals in periapical images of maxillary first and second molars, and to compare the performance of AI ...
Seyed AmirHossein Ourang +8 more
wiley +1 more source
Asma grave en una ciudad tropical a gran altitud.
, 2020 Carlos A. Torres Duque +4 more
openalex +2 more sources
Paracetamol in Pregnancy: Reassurance Amidst Uncertainty
BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
Athina Samara, Asma Khalil
wiley +1 more source
Journal of the European Academy of Dermatology and Venereology, EarlyView.In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba +11 more
wiley +1 more source